CanVirex
CanVirex is a spin-off from Heidelberg University Hospital, developing next-generation measles viruses for cancer immunotherapy. The company aims to create affordable, best-in-class cancer treatments with fewer side effects, leveraging a proprietary platform technology based on measles vectors. With a strategic collaboration with Heidelberg University Hospital and industry partners, CanVirex focuses on innovative immunotherapeutics for cancer and vaccines, with clinical development anticipated to start in 2024.
Industries
Nr. of Employees
small (1-50)
CanVirex
Malzgasse 9, CH – 4052 Basel, Switzerland
Products
Lead oncolytic viral candidate encoding IL-12 (lead oncology candidate, preclinical → early clinical)
A replicating measles-vaccine–derived oncolytic viral candidate engineered to express interleukin-12 (IL-12); preclinical development completed and preparation for early-phase clinical testing to assess safety and tolerability.
Pipeline of measles-vectored oncology and vaccine candidates (discovery to preclinical)
A diversified portfolio of engineered measles-vectored candidates across discovery and preclinical stages for both immuno-oncology and infectious-disease vaccination applications.
Lead oncolytic viral candidate encoding IL-12 (lead oncology candidate, preclinical → early clinical)
A replicating measles-vaccine–derived oncolytic viral candidate engineered to express interleukin-12 (IL-12); preclinical development completed and preparation for early-phase clinical testing to assess safety and tolerability.
Pipeline of measles-vectored oncology and vaccine candidates (discovery to preclinical)
A diversified portfolio of engineered measles-vectored candidates across discovery and preclinical stages for both immuno-oncology and infectious-disease vaccination applications.
Services
Strategic collaborations with clinical research sites and industry partners for research, clinical translation, and manufacturing of viral-vector therapeutics.
Parallel translational testing program to run alongside clinical trials to identify predictive biomarkers and inform patient selection.
Strategic collaborations with clinical research sites and industry partners for research, clinical translation, and manufacturing of viral-vector therapeutics.
Parallel translational testing program to run alongside clinical trials to identify predictive biomarkers and inform patient selection.
Expertise Areas
- Oncolytic viral vector development
- Viral-vector vaccine development
- Translational biomarker programs and patient stratification
- Preclinical candidate discovery and screening
Key Technologies
- Replicating measles vaccine–derived viral vectors
- Transgene insertion and expression in viral genomes
- Oncolytic virotherapy
- Antigen delivery via replicating viral vectors
News & Updates
CanVirex advances its lead candidate, Mevacil, for cancer treatment, preparing for phase I/IIa trial in 2024.
Feature article discussing CanVirex's approach to cancer vaccination and immunotherapy.
Overview of CanVirex's platform deploying recombinant measles vectors for cancer and COVID-19 vaccines.
Introduction to CanVirex's origins and mission to fight cancer with viruses.
CanVirex advances its lead candidate, Mevacil, for cancer treatment, preparing for phase I/IIa trial in 2024.
Feature article discussing CanVirex's approach to cancer vaccination and immunotherapy.
Overview of CanVirex's platform deploying recombinant measles vectors for cancer and COVID-19 vaccines.
Introduction to CanVirex's origins and mission to fight cancer with viruses.